Kymera Therapeutics Inc (NAS:KYMR)
$ 47.74 0.89 (1.9%) Market Cap: 3.09 Bil Enterprise Value: 2.57 Bil PE Ratio: 0 PB Ratio: 3.46 GF Score: 50/100

Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 05:00PM GMT
Release Date Price: $29.5 (+9.14%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Kymera Therapeutics, and presenting on behalf of the company is CEO Nello Mainolfi. There will be a Q&A after the presentation. There will be mics going around the room. And for those tuning in via on the webcast online, feel free to submit a question via the digital conference book. So with that Nello.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Eric. Thanks, everybody, for joining us today. Thanks for the invite Eric and the opportunity to present the story here. So let's start here. Just to provide a bit of context. So Kymera was founded in 2016 with the goal and mission actually to building a fully integrated biotech using targeted protein degradation to develop a new generation of medicines.

Just for those that are not familiar with the technology, I will spend 10 seconds. So targeted protein degradation is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot